Bayer opens Beijing innovation hub for China-discovered medicines
Bayer (BAYN: DE) has opened its first China-based innovation center in Beijing’s E-Town BioPark, positioning the site as a launchpad for local biotechs aiming for global markets. The German pharma said the E-Town Open Innovation Center will integrate startups into its global network and strengthen China’s role in drug discovery.
The facility will work alongside Bayer Co.Lab Connect Beijing, giving young companies access to global research and collaboration resources. Suzhou Puhe BioPharma and Beijing Youngen Technology are the first residents, providing early tests of Bayer’s model for accelerating Chinese innovation.
Puhe has already partnered with Bayer on a small-molecule PRMT5 inhibitor now in a first-in-human study in MTAP-deleted solid tumors. Youngen, focused on siRNA and small nucleic acid therapies for cardiometabolic and other diseases, will receive support as it advances toward clinical development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze